ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0063

Implementability of a SLE Medication Adherence Intervention

Kai Sun1, Nneka Molokwu2, Amy Corneli1, Kathryn Pollak1, Alexandria Bennion2, Jennifer L Rogers3, Rebecca Sadun2, Lisa Criscione-Schreiber1, Jayanth Doss2, Amanda Eudy4, Hayden Bosworth1 and Megan Clowse2, 1Duke University School of Medicine, Durham, NC, 2Duke University, Durham, NC, 3Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC, 4Duke University, Raleigh, NC

Meeting: ACR Convergence 2022

Keywords: health behaviors, Health Services Research, Intervention, Qualitative Research, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Medication nonadherence in SLE is common and negatively impacts patient outcomes. Yet, little is known about how to improve medication adherence in patients with SLE. We developed a provider-led adherence intervention with the goals of identifying nonadherence, improving patient-provider communication, and facilitating logistics and increasing motivation for taking SLE medications. The intervention encourages providers to review real-time refill data with patients; use communication strategies such as validating the patient’s experiences, providing positive reinforcement, and asking open-ended and nonjudgmental questions to encourage discussion; and address identified adherence barriers (Figure 1). Prior pilot testing showed 10% improvement in medication adherence after one visit, and results from provider and patient surveys supported intervention feasibility and acceptability. In the current study, we examined provider fidelity, time spent, and quality of patient-provider communication during the adherence intervention to identify areas for improvement and to inform implementation.

Methods: All providers in an academic lupus clinic were asked to implement the intervention. With patients’ consent, we audio recorded patient encounters during which the adherence intervention was performed. Patients were eligible if they were prescribed SLE-specific medications and had a medication possession ratio < 80% based on pharmacy refill information in the past 3 months. During analysis, we coded whether the clinician shared refill data with the patient, asked open-ended questions regarding adherence, made nonjudgmental statements to normalize missing doses or recognize difficulty taking medications, and used positive reinforcement, such as praising patients for good behaviors observed. Following their clinic visit, patients were invited to participate in in-depth individual interviews about their experiences with the adherence intervention. The interviews were audio-recorded and analyzed using applied thematic analysis.

Results: We recorded and analyzed 24 encounters among six lupus clinic physicians. Patients’ median age was 37, 100% were female, and 75% were Black. Physicians reviewed refill information with patients in 20 encounters, used positive reinforcement in 21, validated the patient in 17, and asked open-ended questions in 11. On average, clinicians spent 3.9 minutes discussing medication adherence.

We interviewed 15 patients. All felt that the amount of time spent discussing lupus medications was “just right” except for one who felt that it was slightly long in the context of an otherwise short visit. Nearly all patients described having a positive experience with the adherence intervention.

Conclusion: We provide additional evidence to support the feasibility of incorporating the adherence intervention into routine clinical care and acceptability by patients. We also found an opportunity to improve provider training in asking open-ended questions and using patient validation when communicating with patients about medication adherence. Future work should test the intervention in a larger controlled setting.

Supporting image 1

Figure 1. Adherence intervention workflow with screenshot of pharmacy refill data and example language.


Disclosures: K. Sun, None; N. Molokwu, None; A. Corneli, None; K. Pollak, None; A. Bennion, None; J. Rogers, None; R. Sadun, None; L. Criscione-Schreiber, GlaxoSmithKlein(GSK); J. Doss, Pfizer; A. Eudy, GlaxoSmithKlein(GSK), Pfizer, Exagen; H. Bosworth, Boehringer-Ingelheim, BeBetter Therapeutics, nordisk, Merck/MSD, Improved Patient Outcomes, otuska, sanofi, walmart; M. Clowse, Exagen.

To cite this abstract in AMA style:

Sun K, Molokwu N, Corneli A, Pollak K, Bennion A, Rogers J, Sadun R, Criscione-Schreiber L, Doss J, Eudy A, Bosworth H, Clowse M. Implementability of a SLE Medication Adherence Intervention [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/implementability-of-a-sle-medication-adherence-intervention/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/implementability-of-a-sle-medication-adherence-intervention/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology